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ABSTRACT
Pulmonary capillary hemangiomatosis (PCH) is a rare and controversial entity that is known to be a cause of pulmonary 
hypertension and is microscopically characterized by proliferation of dilated capillary-sized channels along and in the 
alveolar walls. Clinically, it is mostly seen in adults. Clinical features are characterized by nonspecific findings such as 
shortness of breath, cough, chest pain, and fatigue. It can be clinically indistinguishable from pre-capillary pulmonary 
arterial hypertension disorders such as primary pulmonary arterial hypertension (PAH) or chronic thromboembolic 
pulmonary hypertension. However, the diagnostic distinction, which usually requires a multidisciplinary approach, is 
crucial in order to avoid inappropriate treatment with vasodilator medications usually used for PAH treatment. Prognosis 
of PCH remains poor with lung transplant being the only definitive treatment. We report an autopsy case of pulmonary 
capillary hemangiomatosis unmasked at autopsy that was treated with a prostacyclin analog, usually contraindicated in 
such patients. We emphasize that this entity should always be on the differential diagnosis in a patient with pulmonary 
hypertension and requires great vigilance on the part of the clinician, radiologist and pathologist to make the diagnosis 
and guide appropriate management. 
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INTRODUCTION
Pulmonary capillary hemangiomatosis (PCH) is 
a rare entity in which patients typically present with 
pulmonary hypertension.1-6 The disease does not have a 
sexual predilection. Unfortunately, the diagnosis of PCH 
is usually not made until an autopsy is performed.1-6 It is 
microscopically characterized by an abnormal proliferation 
of thin-walled microvessels expanding the alveolar 
septum and encompassing bronchovascular bundles.3 
Imaging findings include widespread geographic regions 
of pulmonary ground glass attenuation and pulmonary 
hypertension. Familiarity with this entity is crucial as 
conventional therapies such as vasodilators utilized for 
treating pulmonary hypertension are contraindicated in 
PCH and can actually exacerbate the disease.2 The overall 
prognosis remains poor with lung transplant being the 
sole definitive treatment.2,4
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CASE REPORT
We report a case of a 67-year-old female with a 
history of right heart failure, and COPD that presented 
for dyspnea, dizziness, and near syncope episodes. 
The patient had symptoms of dyspnea on exertion 
for many years prior and had been on 4 L oxygen 
by nasal cannula. She was referred for a cardiac 
consultation when it was revealed that she had proven 
pulmonary hypertension by echocardiogram and 
right heart catheterization. In particular, right heart 
catheterization demonstrated the mean pulmonary 
capillary wedge pressure and mean pulmonary 
artery pressure were 12 mmHg (reference range: 
2-15 mmHg) and 54 mmHg (reference range: 
8-20 mmHg), respectively, suggestive of severe 
pre-capillary pulmonary hypertension. Cardiac output 
(4.42L/min; reference range: 4-8L/min) and cardiac 
index (2.55; reference range: 2.5-4 L/min/m2) were 
normal, indicative of preserved left heart function. 
The mean central venous pressure (14 mm Hg; 
reference range: 8-12 mmHg) and mean right atrial 
pressure (13 mmHg; reference range: 2-6 mmHg) were 
elevated and suggestive of right heart failure.
A chest computed tomography (CT) performed, at 
that time, demonstrated emphysema at the pulmonary 
apices and areas of dense ground glass opacifications 
without definite honeycombing, ruling out interstitial 
lung disease. However, imaging findings were 
consistent with pulmonary hypertension, although 
etiologies such as PCH were on the differential and 
could not be definitively excluded (Figures 1 and 2).
Figure 1. Imaging findings associated with PCH, as seen on non-contrasted chest CT in soft tissue windows. 
A and B – axial views demonstrate evidence of significant pulmonary hypertension manifested by enlargement 
of the main pulmonary artery (thick white arrow) which measured 3.6 cm, as well as marked enlargement of the 
right atrium (thin white arrow) and right ventricle (white arrowhead); C (coronal view) and D (axial view) show the 
enlarged mediastinal and hilar lymph nodes, nonspecific, but which in the setting of pulmonary hypertension can 
be associated with PCH.
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Subsequent pulmonary function tests revealed 
abnormalities that were consistent with her known 
history of pulmonary emphysema. After comprehensive 
evaluations, it was concluded that she had pulmonary 
hypertension that was likely secondary to multifactorial 
lung disease. She then began treatment for pulmonary 
hypertension and was also started on a high dose of 
corticosteroids and sildenafil, a prostacyclin analog.
Months later, she presented again with worsening 
respiratory distress and was hospitalized due to 
exacerbations of her heart failure. She had her oxygen 
supplementation increased to improve symptoms. 
Increased doses of medications offered little help. 
Her laboratory values continued to increase with 
a brain natriuretic peptide (BNP) of 3580 pg/mL 
(reference range [RR] < 100 pg/mL) and worsening 
kidney function. A chest X-ray revealed an enlarging 
cardiac silhouette with increased pulmonary vascular 
congestion relative to earlier imaging. On her last 
admission, she required 15 L of oxygen with BIPAP 
in order to maintain her oxygen saturation. Her chest 
CT at this time also showed evidence of worsening 
disease. After clinical consensus, the steroid was 
tapered off, and sildenafil was discontinued. She was 
started on comfort care treatment and made DNAR 
and expired soon thereafter. A lung only autopsy was 
performed.
AUTOPSY PRESENTATION
On gross examination, both lungs demonstrated 
patchy emphysematous changes and areas of 
consolidation (Figure 3).
Histopathologically, focal areas of passive 
congestion were identified with increased septal 
capillary densities, capillary proliferation and associated 
pulmonary hypertension (Figure 4). Special stains 
of such areas demonstrated aberrant capillary 
proliferation and layering, with immunohistochemical 
stains of endothelial markers confirming this impression 
(Figure 5). A diagnosis of pulmonary capil lary 
hemangiomatosis was rendered.
Figure 2. Imaging findings associated with PCH, as seen on non-contrasted chest CT in lung windows. 
A to F – sequential axial slices from the upper lung zones down to the lower lung zones demonstrate widespread 
geographic regions of pulmonary ground glass attenuation, which in the setting of pulmonary hypertension, raises 
the possibility of PCH. Although indistinguishable from PVOD on imaging alone, the relative paucity of septal 
thickening as compared to the degree of the ground-glass present may somewhat favor PCH over PVOD in the 
differential diagnostic consideration.
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Figure 3. Gross findings of the lungs at autopsy (post-formalin fixation). A – Right; B – Left lung parenchyma 
revealing emphysematous changes and areas of consolidation with firm pulmonary parenchyma.
Figure 4. Photomicrographs of the lung. A – thickened alveolar walls with increased capillary density and passive 
congestion; B – increased capillary density and congestion in the alveolar walls with hemosiderin-laden macrophages 
in the alveolar spaces; C – Muscularized arteriole within the alveolar septa with intimal thickening and medial 
hypertrophy characteristic of pulmonary hypertension (H&E, A 40X, B 100X, C 100X).
Figure 5. Photomicrographs of the lung. A – Iron staining highlights hemosiderin in alveolar walls and in the 
alveolar spaces (Perls Prussian blue stain, 100X); B – reticulin stain revealing the increased number of capillary walls 
in alveolar walls (Verhoeff van Gieson stain, 100X); C – CD31 stain revealing increase vessel proliferation in alveolar 
walls (100X).
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DISCUSSION
Pulmonary capillary hemangiomatosis is a rare 
cause of pulmonary hypertension that is typically seen 
in younger adults but can occur in an age range from 
2 years to 72 years.
The etiology of PCH remains unknown, and 
its prognosis is invariably unfavorable with death 
occurring within 3-5 years from the diagnosis. Patients 
typically present with progressive dyspnea as their 
major complaint but can also have hemoptysis, chest 
pain, cough, and fatigue.1-6 Their pulmonary function 
tests are usually normal.2 Right heart catheterization 
reveals markedly pulmonary hypertension.2,3
Therapeutically, PCH patients do not respond to 
conventional therapy for pulmonary hypertension such 
as diuretics, ACE-inhibitors, warfarin, and steroids.2 
Noteworthy, the addition of prostacyclin analog 
to the therapeutic regimen of these patients have 
been reported to have a disastrous outcome such as 
sudden-onset of respiratory distress. Therefore, the 
use of prostacyclin analogs is not indicated.2 The only 
definitive treatment is lung transplantation, although a 
case of recurrence in this setting has been reported. 2,4
Pulmonary capillary hemangiomatosis (PCH) (and 
its closely related condition Pulmonary Veno-occlusive 
Disease-PVOD) can be clinically indistinguishable from 
pre-capillary pulmonary arterial hypertension disorders 
such as primary pulmonary arterial hypertension (PAH) 
or chronic thromboembolic pulmonary hypertension. 
However, the diagnostic distinction is crucial to avoid 
inappropriate treatment with vasodilator medications 
usually used for PAH treatment (i.e., prostacyclin 
agonists, endothelin antagonists, calcium channel 
blockers, phosphodiesterase-5 inhibitors), as these 
agents can cause pulmonary edema for PCH/PVOD 
patients. The diagnostic distinction is also important 
to prompt timely evaluation for possible lung 
transplantation, given the rapid progression to 
end-stage disease and death. Although imaging 
features can remain nonspecific, the radiologist 
may raise the question of an otherwise unsuspected 
capillary/postcapillary disorder suggestive of PCH/PVOD, 
with high-resolution CT as the preferred modality for 
optimal radiological evaluation.
Imaging characteristics of PCH involve, in general, 
the presence of pulmonary artery hypertension, such 
as enlarged pulmonary arteries. Also, as pulmonary 
artery hypertension progresses, evidence of secondary 
right heart dysfunction can be seen with typical CT 
imaging findings of right ventricular hypertrophy, 
leftward bowing of the interventricular septum, right 
atrial enlargement, and reflux of IV contrast into the 
inferior vena cava and hepatic veins.
More specific findings that can help to distinguish 
PCH/PVOD from pre-capillary causes of pulmonary 
arterial hypertension (such primary pulmonary 
hypertension and chronic thromboembolic pulmonary 
hypertension) include the presence of pulmonary 
smooth interstitial/interlobular septal thickening, 
geographic or nodular ground-glass opacities, and 
pleural effusion, which can be caused by elevated 
capillary (or postcapillary) pressure. These findings, 
particularly interlobular septal thickening, are therefore 
less typical of precapillary causes of pulmonary artery 
hypertension.7 Downstream postcapillary causes of 
pulmonary hypertension (such as mitral stenosis, left 
ventricular failure, or left atrial myxoma) may also 
demonstrate these manifestations, but will often 
demonstrate pulmonary venous dilation (absent in 
PCH/PVOD) as well as other more specific findings 
consistent with their respective conditions, such as 
mitral valve calcifications, left atrial filling defect, 
and left ventricular enlargement. Additionally, 
lymphadenopathy is more commonly associated with 
PCH/PVOD than with other pre-capillary causes of 
pulmonary hypertension, probably secondary to venous 
congestion and veno-lymphatic shunts in PCH/PVOD.8,9
In the context of pulmonary hypertension, when 
smooth septal thickening and ground glass opacities 
are seen or when enlarged mediastinal lymph nodes 
are present, both PCH and PVOD should be considered 
in the imaging differential diagnosis.7,9 Further 
distinguishing these two conditions radiologically 
can be difficult as they share many imaging features. 
However, relatively more conspicuous or widespread 
centrilobular and lobular ground-glass opacities, and 
relative paucity of septal thickening, may favor PCH 
over PVOD; and vice versa, relatively more conspicuous 
septal thickening with absent or less centrilobular 
ground glass nodules may favor PVOD over PCH.7 
Additionally, mediastinal lymphadenopathy may be 
present with PCH more likely than with PVOD.2
In the imaging workup of PCH, the CT is the 
preferred modality for optimal characterization of 
its imaging features. Nuclear imaging VQ-scanning 
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i s  somet imes  done  as  pa r t  o f  the  imag ing 
workup, particularly when chronic pulmonary 
thromboembolism is in the differential diagnosis for 
pulmonary artery hypertension, however VQ scanning 
is not helpful for either confirming or excluding PCH; 
VQ scan findings in PCH include the entire spectrum 
from normal to small or large perfusion mismatched 
defects possible.10
Upon a gross exam, the lungs will typically appear 
congested and have an edematous and firm appearance 
without significant fibrosis. Histopathologically, 
at low power, areas of the lung involved by PCH 
demonstrate passive congestion.3 At higher power, 
an abnormal proliferation of thin-walled microvessels 
expanding the alveolar septum and encompassing 
bronchovascular bundles can be characteristically 
identified.3 These proliferations can infiltrate small 
pulmonary arteries and interlobular veins, causing an 
obstruction and resultant PAH.3 Such proliferations are 
also prone to bleeding which results in hemorrhage 
and hemosiderin-laden macrophages in the alveolar 
spaces. In order to make the diagnosis of PCH, 
there must be at least 2 layers of aberrant capillaries 
that are seen within the alveolar wall.2,3 The typical 
characteristics of pulmonary hypertension will also 
be seen, which include intimal thickening and medial 
hypertrophy of the small muscular arterioles, but in 
contrast to other forms of pulmonary hypertension, 
the presence of plexiform lesions will not be observed.3 
Special stains and immunohistochemistry are not 
necessary to diagnose but are helpful for the diagnosis 
of pulmonary capillary hemangiomatosis.2,3 Endothelial 
markers such as CD31, or CD34 will highlight the 
proliferation of septal capillary endothelial cells.2,3
Common misdiagnoses include PVOD and 
pulmonary arteriopathy.1,5 However, in both entities 
the capillary proliferation lacks.1-3 A Trichrome, or a 
Movat Pentachrome stain can highlight the supporting 
collagen of the loop lesion and occluded veins seen 
in PVOD but not in PCH. However, PCH like findings 
and PVOD like findings have been documented in both 
entities interchangeably, raising the possibility that 
these distinct entities may represent spectrums of the 
same disease.3 Interestingly, such findings have also 
been reported in patients who do not have pulmonary 
hypertension3.
CONCLUSION(S)
Overall, in our patient’s case, the pulmonary 
artery hypertension presumably involved multiple 
contributing factors, including a contributing element 
from chronic obstructive pulmonary disease (COPD) in 
addition to her PCH. Additionally it is possible the PCH 
developed as a reactive process due to hypoxia and 
chronic congestion, rather than a primary/idiopathic 
etiology, in this patient with multiple additional 
conditions that could contribute to pulmonary 
hypertension.11 However, regardless of the primary 
or secondary etiology, considering the presence of 
PCH remains diagnostically important since it still has 
important unique clinical consequences, specifically, 
avoiding typical vasodilatory therapy and early 
potential transplant planning.
This autopsy case highlights the importance of 
due vigilance in pulmonary hypertension patients and 
the multidisciplinary approach required to establish a 
diagnosis of pulmonary capillary hemangiomatosis and 
appropriately guide management. Although the clinical 
symptoms are non-specific, findings suggestive of PCH 
can be radiologically suspected, which can indicate a 
subsequent biopsy. However, histology remains the 
sole reliable means to make the diagnosis when the 
lungs have been adequately sampled. Most of the time, 
the diagnosis is not suspected or masked by coexisting 
lung disease, adequate lung tissue is not sampled, or 
the patient is inappropriately treated, and thus, most 
cases of PCH are unmasked at autopsy. Lesson learned, 
recognition of this rare entity is imperative to convey 
accurate prognosis and appropriately guide patient 
management, avoiding treatment with prostacyclin 
analogs (conventionally used to treat pulmonary 
hypertension) which may end up actually exacerbating 
the disease process in these patients.
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